StockDriftsStockDriftsTop 8 Versant Venture Management LLC Holdings
| Stock | Company | % Port. | Shares | Value | Activity | Ownership | Avg. Cost | Date |
|---|---|---|---|---|---|---|---|---|
| GLUE | Monte Rosa Therapeutics, Inc. | 47.34% | 3.18M | $77.0M | +0.00%(+0) | $6.12(+153.27%) | 2026-06-30 | |
| IPSC | Century Therapeutics, Inc. | 18.33% | 12.17M | $29.8M | +0.00%(+0) | $1.63(+17.97%) | 2026-06-30 | |
| JBIO | Jade Biosciences, Inc. | 13.55% | 991.8K | $22.0M | -35.00%(-534.04K) | $49.27(-49.85%) | 2026-06-30 | |
| LENZ | Lenz Therapeutics, Inc. | 9.28% | 2.66M | $15.1M | +0.00%(+0) | $37.95(-87.53%) | 2026-06-30 | |
| CTNM | Contineum Therapeutics, Inc. | 5.47% | 542.6K | $8.9M | +0.00%(+0) | $17.61(-19.42%) | 2026-06-30 | |
| CRSP | CRISPR Therapeutics AG | 4.99% | 148.8K | $8.1M | +0.00%(+0) | $0.00 | 2026-06-30 | |
| SKYE | Skye Bioscience, Inc. | 0.86% | 2.01M | $1.4M | +0.00%(+0) | $9.18(-94.53%) | 2026-06-30 | |
| TPST | Tempest Therapeutics, Inc. | 0.18% | 269.8K | $299K | +0.00%(+0) | $14.53(-91.95%) | 2026-06-30 |
| Performance Metric | 3-Year Annualized | 3-Year Cumulative | 5-Year Annualized | 5-Year Cumulative |
|---|---|---|---|---|
| Top 20 Holdings Weighted | -6.19% | -17.45% | -30.21% | -83.44% |
| Top 20 Holdings Unweighted | -17.58% | -44.00% | -37.39% | -90.38% |
Versant Venture Management LLC reports $162.61M in US-listed equity holdings across 8 positions in its most recent 13F filing. Its largest disclosed positions are GLUE (47.3%), IPSC (18.3%) and JBIO (13.6%). The top 20 holdings account for 100% of reported assets. Its disclosed equity book has returned -17.45% on a three-year cumulative basis. Figures reflect the Q2 2026 filing.
Portfolio changes
Every reported change this quarter, grouped by direction. The signal is in the rotation, not any single trade.
Sign up free to track Versant Venture Management LLC, compare funds side by side, and get alerts the moment positions change.
Holdings on this page are parsed from Versant Venture Management LLC’s Form 13F filings with the U.S. Securities and Exchange Commission (CIK 1560009). View Versant Venture Management LLC’s 13F filings on SEC